We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
Organon (OGN - Free Report) reported $1.6 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 7.6%. EPS of $0.88 for the same period compares to $0.81 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.55 billion, representing a surprise of +3.06%. The company delivered an EPS surprise of +10.00%, with the consensus EPS estimate being $0.80.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Organon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Women's Health- U.S.- Nexplanon/Implanon NXT: $154 million compared to the $155.42 million average estimate based on three analysts. The reported number represents a change of -10.5% year over year.
Revenue- Women's Health- U.S.- Follistim AQ: $51 million versus $28.70 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +96.2% change.
Revenue- Established Brands- U.S.- Respiratory- Other: $8 million versus $12.57 million estimated by three analysts on average.
Revenue- Established Brands- Int'l- Non-Opioid Pain, Bone and Dermatology- Other: $64 million compared to the $58.85 million average estimate based on three analysts. The reported number represents a change of +14.3% year over year.
Revenue- Women's Health- Nexplanon/Implanon NXT: $231 million versus the three-analyst average estimate of $231.62 million. The reported number represents a year-over-year change of -3.4%.
Revenue- Women's Health- Follistim AQ: $83 million versus the three-analyst average estimate of $59.85 million. The reported number represents a year-over-year change of +66%.
Revenue- Biosimilars Total: $199 million versus $162.27 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +48.5% change.
Revenue- Women?s Health Total: $465 million versus the three-analyst average estimate of $438.21 million. The reported number represents a year-over-year change of +7.4%.
Revenue- Other Total: $19 million compared to the $34.05 million average estimate based on three analysts. The reported number represents a change of -36.7% year over year.
Revenue- Established Brands- Non-Opioid Pain, Bone and Dermatology- Other: $67 million compared to the $62.48 million average estimate based on three analysts. The reported number represents a change of +8.1% year over year.
Revenue- Women's Health- NuvaRing: $35 million versus the three-analyst average estimate of $35.74 million. The reported number represents a year-over-year change of -12.5%.
Revenue- Biosimilars- Renflexis: $77 million versus the three-analyst average estimate of $68.82 million. The reported number represents a year-over-year change of +28.3%.
Shares of Organon have returned +2.9% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Organon (OGN - Free Report) reported $1.6 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 7.6%. EPS of $0.88 for the same period compares to $0.81 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.55 billion, representing a surprise of +3.06%. The company delivered an EPS surprise of +10.00%, with the consensus EPS estimate being $0.80.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Organon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Women's Health- U.S.- Nexplanon/Implanon NXT: $154 million compared to the $155.42 million average estimate based on three analysts. The reported number represents a change of -10.5% year over year.
- Revenue- Women's Health- U.S.- Follistim AQ: $51 million versus $28.70 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +96.2% change.
- Revenue- Established Brands- U.S.- Respiratory- Other: $8 million versus $12.57 million estimated by three analysts on average.
- Revenue- Established Brands- Int'l- Non-Opioid Pain, Bone and Dermatology- Other: $64 million compared to the $58.85 million average estimate based on three analysts. The reported number represents a change of +14.3% year over year.
- Revenue- Women's Health- Nexplanon/Implanon NXT: $231 million versus the three-analyst average estimate of $231.62 million. The reported number represents a year-over-year change of -3.4%.
- Revenue- Women's Health- Follistim AQ: $83 million versus the three-analyst average estimate of $59.85 million. The reported number represents a year-over-year change of +66%.
- Revenue- Biosimilars Total: $199 million versus $162.27 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +48.5% change.
- Revenue- Women?s Health Total: $465 million versus the three-analyst average estimate of $438.21 million. The reported number represents a year-over-year change of +7.4%.
- Revenue- Other Total: $19 million compared to the $34.05 million average estimate based on three analysts. The reported number represents a change of -36.7% year over year.
- Revenue- Established Brands- Non-Opioid Pain, Bone and Dermatology- Other: $67 million compared to the $62.48 million average estimate based on three analysts. The reported number represents a change of +8.1% year over year.
- Revenue- Women's Health- NuvaRing: $35 million versus the three-analyst average estimate of $35.74 million. The reported number represents a year-over-year change of -12.5%.
- Revenue- Biosimilars- Renflexis: $77 million versus the three-analyst average estimate of $68.82 million. The reported number represents a year-over-year change of +28.3%.
View all Key Company Metrics for Organon here>>>Shares of Organon have returned +2.9% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.